Vivos Therapeutics Q2 FY26 net loss widens to $5.52 million; revenue rises 35% to $5.2 million

Reuters2026/08/14 20:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vivos Therapeutics posted Q2 revenue of $5.2 million, up 35% from a year earlier, as service revenue climbed to $3.8 million.
Net loss widened to $5.52 million, while loss per share narrowed to $0.31.
Gross margin rose 2 percentage points to 57%, while operating loss held roughly flat at $4.83 million.
Cash and cash equivalents fell to $1.77 million at June 30, while stockholders’ equity deficit widened to $3.82 million.
CEO Kirk Huntsman cited rising referrals and program revenue in Nevada centers, progress on SCN’s AI-enabled software conversion, and expanded capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141628PRIMZONEFULLFEED9810649) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vivos Therapeutics Q2 FY26 net loss widens to $5.52 million; revenue rises 35% to $5.2 million

You may also like

Crypto prices